Source: Clinical Chemistry. Conference titles: AACC Annual Meeting. Unidades: FCF, HU
Subjects: POLIMORFISMO, EXPRESSÃO GÊNICA, FARMACOGENÉTICA
ABNT
WILLRICH, Maria Alice Vieira et al. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 24 abr. 2024. , 2007APA
Willrich, M. A. V., Hirata, M. H., Bernik, M. M. S., Dorea, E. L., Bertolami, M. C., Faludi, A. A., & Hirata, R. D. C. (2007). CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Willrich MAV, Hirata MH, Bernik MMS, Dorea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. 2007 ; 53( 6): A151.[citado 2024 abr. 24 ]Vancouver
Willrich MAV, Hirata MH, Bernik MMS, Dorea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. 2007 ; 53( 6): A151.[citado 2024 abr. 24 ]